Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Travere Therapeutics, Inc. (TVTX)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Travere Therapeutics, Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 1438533.
Total stock buying since 2015: $165,815.
Total stock sales since 2015: $27,458,794.
Total stock option exercises since 2015: $3,894,352.
Table 3. Detailed insider trading at Travere Therapeutics, Inc. (TVTX) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2021-02-17 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 27.35 | 34,187 |
| 2021-02-08 | Heerma Peter (Chief Commercial Officer) | Sale | 1,125 | 31.58 | 35,527 |
| 2021-02-08 | Dube Eric M (Chief Executive Officer) | Sale | 4,813 | 31.58 | 151,994 |
| 2021-02-08 | Rote William E. (Senior Vice President, R&D) | Sale | 2,250 | 31.58 | 71,055 |
| 2021-02-08 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,125 | 31.58 | 35,527 |
| 2021-02-08 | Clague Laura (Chief Financial Officer) | Sale | 2,250 | 31.58 | 71,055 |
| 2021-02-08 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,250 | 31.58 | 71,055 |
| 2021-02-05 | Heerma Peter (Chief Commercial Officer) | Sale | 1,125 | 31.41 | 35,336 |
| 2021-02-05 | Dube Eric M (Chief Executive Officer) | Sale | 4,813 | 31.41 | 151,176 |
| 2021-02-05 | Rote William E. (Senior Vice President, R&D) | Sale | 2,250 | 31.41 | 70,672 |
| 2021-02-05 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,125 | 31.41 | 35,336 |
| 2021-02-05 | Clague Laura (Chief Financial Officer) | Sale | 2,250 | 31.41 | 70,672 |
| 2021-02-05 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,250 | 31.41 | 70,672 |
| 2021-02-03 | Heerma Peter (Chief Commercial Officer) | Sale | 563 | 28.91 | 16,276 |
| 2021-02-03 | Dube Eric M (Chief Executive Officer) | Sale | 2,406 | 28.91 | 69,557 |
| 2021-02-03 | Rote William E. (Senior Vice President, R&D) | Sale | 3,625 | 28.91 | 104,798 |
| 2021-02-03 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,813 | 28.91 | 52,413 |
| 2021-02-03 | Clague Laura (Chief Financial Officer) | Sale | 3,625 | 28.91 | 104,798 |
| 2021-02-03 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 3,175 | 28.91 | 91,789 |
| 2021-02-02 | Heerma Peter (Chief Commercial Officer) | Sale | 563 | 30.75 | 17,312 |
| 2021-02-02 | Dube Eric M (Chief Executive Officer) | Sale | 8,734 | 30.17 | 263,530 |
| 2021-02-02 | Rote William E. (Senior Vice President, R&D) | Sale | 3,625 | 30.75 | 111,468 |
| 2021-02-02 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,813 | 30.75 | 55,749 |
| 2021-02-02 | Clague Laura (Chief Financial Officer) | Sale | 3,625 | 30.75 | 111,468 |
| 2021-02-02 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 3,175 | 30.75 | 97,631 |
| 2021-02-02 | Aselage Steve (Director) | Sale | 25,000 | 30.75 | 768,750 |
| 2021-02-02 | Aselage Steve (Director) | Option Ex | 25,000 | 10.09 | 252,250 |
| 2021-01-06 | Dube Eric M (Chief Executive Officer) | Sale | 3,438 | 27.01 | 92,860 |
| 2021-01-06 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 688 | 27.01 | 18,582 |
| 2021-01-05 | Dube Eric M (Chief Executive Officer) | Sale | 3,438 | 26.65 | 91,622 |
| 2021-01-05 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 688 | 26.65 | 18,335 |
| 2020-12-15 | Aselage Steve (Director) | Sale | 5,549 | 26.02 | 144,384 |
| 2020-12-02 | Aselage Steve (Director) | Sale | 7,891 | 23.43 | 184,846 |
| 2020-11-25 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 22.72 | 85,200 |
| 2020-11-24 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 23.86 | 89,475 |
| 2020-11-16 | Rote William E. (Senior Vice President, R&D) | Sale | 2,500 | 23.96 | 59,900 |
| 2020-11-16 | Clague Laura (Chief Financial Officer) | Sale | 7,500 | 23.98 | 179,812 |
| 2020-11-16 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,500 | 23.98 | 59,950 |
| 2020-11-13 | Rote William E. (Senior Vice President, R&D) | Sale | 2,500 | 23.62 | 59,055 |
| 2020-11-13 | Clague Laura (Chief Financial Officer) | Sale | 7,500 | 23.61 | 177,075 |
| 2020-11-13 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,500 | 23.62 | 59,045 |
| 2020-11-06 | Aselage Steve (Director) | Sale | 20,625 | 23.00 | 474,375 |
| 2020-11-05 | Aselage Steve (Director) | Sale | 2,500 | 21.26 | 53,150 |
| 2020-10-05 | Heerma Peter (Chief Commercial Officer) | Sale | 2,188 | 19.35 | 42,337 |
| 2020-10-02 | Heerma Peter (Chief Commercial Officer) | Sale | 2,188 | 18.90 | 41,353 |
| 2020-09-23 | Rote William E. (Senior Vice President, R&D) | Sale | 1,500 | 18.48 | 27,720 |
| 2020-09-23 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 750 | 18.48 | 13,860 |
| 2020-09-23 | Clague Laura (Chief Financial Officer) | Sale | 1,500 | 18.48 | 27,720 |
| 2020-09-23 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,500 | 18.48 | 27,720 |
| 2020-09-22 | Rote William E. (Senior Vice President, R&D) | Sale | 1,500 | 18.59 | 27,885 |
| 2020-09-22 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 750 | 18.59 | 13,942 |
| 2020-09-22 | Clague Laura (Chief Financial Officer) | Sale | 1,500 | 18.59 | 27,885 |
| 2020-09-22 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,500 | 18.59 | 27,885 |
| 2020-09-21 | Dube Eric M (Chief Executive Officer) | Sale | 10,805 | 19.28 | 208,352 |
| 2020-07-28 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 870 | 20.49 | 17,826 |
| 2020-06-25 | Aselage Steve (Director) | Sale | 10,000 | 20.00 | 200,000 |
| 2020-05-14 | Aselage Steve (Director) | Sale | 3,062 | 15.09 | 46,205 |
| 2020-05-13 | Aselage Steve (Director) | Sale | 4,063 | 16.41 | 66,673 |
| 2020-05-12 | Rote William E. (Senior Vice President, R&D) | Sale | 1,339 | 17.07 | 22,859 |
| 2020-05-12 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 527 | 16.98 | 8,950 |
| 2020-05-12 | Clague Laura (Chief Financial Officer) | Sale | 1,777 | 17.07 | 30,336 |
| 2020-05-12 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,052 | 17.07 | 17,959 |
| 2020-05-12 | Aselage Steve (Director) | Sale | 1,000 | 17.16 | 17,160 |
| 2020-05-11 | Rote William E. (Senior Vice President, R&D) | Sale | 813 | 14.95 | 12,154 |
| 2020-05-11 | Clague Laura (Chief Financial Officer) | Sale | 1,250 | 14.95 | 18,687 |
| 2020-05-11 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 525 | 14.95 | 7,848 |
| 2020-05-05 | Aselage Steve (Director) | Sale | 2,500 | 15.88 | 39,700 |
| 2020-03-10 | Rote William E. (Senior Vice President, R&D) | Sale | 3,250 | 14.87 | 48,327 |
| 2020-03-10 | Clague Laura (Chief Financial Officer) | Sale | 4,000 | 15.02 | 60,080 |
| 2020-03-10 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 3,500 | 15.02 | 52,570 |
| 2020-03-05 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,790 | 15.36 | 27,487 |
| 2020-03-05 | Aselage Steve (Director) | Sale | 4,359 | 15.36 | 66,936 |
| 2020-02-18 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 16.55 | 20,687 |
| 2020-02-14 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 16.72 | 20,900 |
| 2020-02-05 | Aselage Steve (Director) | Sale | 2,500 | 16.62 | 41,550 |
| 2020-01-08 | Dube Eric M (Chief Executive Officer) | Sale | 3,750 | 15.14 | 56,775 |
| 2020-01-08 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 750 | 15.14 | 11,355 |
| 2020-01-07 | Dube Eric M (Chief Executive Officer) | Sale | 3,750 | 13.94 | 52,275 |
| 2020-01-07 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 750 | 13.94 | 10,455 |
| 2019-11-29 | Aselage Steve (Director) | Sale | 5,000 | 13.91 | 69,555 |
| 2019-07-31 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,250 | 20.07 | 25,087 |
| 2019-07-30 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,250 | 19.82 | 24,775 |
| 2019-05-16 | Mcfarlane Neil F. (Chief Operating Officer) | Sale | 984 | 18.71 | 18,410 |
| 2019-05-16 | Clague Laura (Chief Financial Officer) | Sale | 1,250 | 18.71 | 23,387 |
| 2019-05-15 | Rote William E. (Senior Vice President, R&D) | Sale | 812 | 17.76 | 14,421 |
| 2019-05-15 | Mcfarlane Neil F. (Chief Operating Officer) | Sale | 984 | 17.78 | 17,495 |
| 2019-05-15 | Clague Laura (Chief Financial Officer) | Sale | 1,250 | 17.78 | 22,225 |
| 2019-05-15 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 525 | 17.71 | 9,297 |
| 2019-05-15 | Aselage Steve (Director) | Sale | 1,838 | 17.82 | 32,753 |
| 2019-05-14 | Rote William E. (Senior Vice President, R&D) | Sale | 813 | 17.78 | 14,455 |
| 2019-05-14 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 525 | 17.75 | 9,318 |
| 2019-05-14 | Aselage Steve (Director) | Sale | 1,838 | 17.79 | 32,698 |
| 2019-02-19 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 21.52 | 26,900 |
| 2019-02-15 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 21.44 | 26,800 |
| 2019-02-12 | Rote William E. (Senior Vice President, R&D) | Sale | 992 | 21.50 | 21,328 |
| 2019-02-12 | Clague Laura (Chief Financial Officer) | Sale | 1,016 | 21.50 | 21,844 |
| 2019-02-12 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 884 | 21.50 | 19,006 |
| 2019-02-12 | Aselage Steve (Chief Executive Officer) | Sale | 1,065 | 21.50 | 22,897 |
| 2019-02-11 | Rote William E. (Senior Vice President, R&D) | Sale | 993 | 21.38 | 21,230 |
| 2019-02-11 | Clague Laura (Chief Financial Officer) | Sale | 1,017 | 21.38 | 21,743 |
| 2019-02-11 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 885 | 21.38 | 18,921 |
| 2019-02-11 | Aselage Steve (Chief Executive Officer) | Sale | 1,065 | 21.38 | 22,769 |
| 2019-01-09 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 750 | 23.82 | 17,865 |
| 2019-01-08 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 750 | 24.09 | 18,067 |
| 2018-12-21 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 22.00 | 82,518 |
| 2018-12-21 | Aselage Steve (Chief Executive Officer) | Sale | 6,188 | 22.02 | 136,259 |
| 2018-12-20 | Mcfarlane Neil F. (Chief Operating Officer) | Sale | 11,125 | 22.28 | 247,865 |
| 2018-12-20 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 22.08 | 82,803 |
| 2018-12-20 | Aselage Steve (Chief Executive Officer) | Sale | 6,188 | 21.97 | 135,956 |
| 2018-12-07 | Aselage Steve (Chief Executive Officer) | Sale | 10 | 24.04 | 240 |
| 2018-11-15 | Rote William E. (Senior Vice President, R&D) | Sale | 2,500 | 24.54 | 61,342 |
| 2018-11-15 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 24.46 | 91,743 |
| 2018-11-15 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,500 | 24.62 | 61,550 |
| 2018-11-15 | Aselage Steve (Chief Executive Officer) | Sale | 5,550 | 24.48 | 135,875 |
| 2018-11-14 | Rote William E. (Senior Vice President, R&D) | Sale | 2,500 | 24.09 | 60,235 |
| 2018-11-14 | Mcfarlane Neil F. (Chief Operating Officer) | Sale | 10,000 | 24.14 | 241,370 |
| 2018-11-14 | Clague Laura (Chief Financial Officer) | Sale | 3,750 | 24.08 | 90,315 |
| 2018-11-14 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,500 | 24.09 | 60,235 |
| 2018-11-14 | Aselage Steve (Chief Executive Officer) | Sale | 5,550 | 24.11 | 133,782 |
| 2018-08-31 | Aselage Steve (Chief Executive Officer) | Sale | 12,000 | 32.00 | 384,000 |
| 2018-08-31 | Aselage Steve (Chief Executive Officer) | Option Ex | 12,000 | 8.70 | 104,399 |
| 2018-03-07 | Aselage Steve (Chief Executive Officer) | Option Ex | 278 | 6.00 | 1,668 |
| 2018-02-14 | Rote William E. (Senior Vice President, R&D) | Sale | 1,034 | 21.50 | 22,232 |
| 2018-01-05 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 942 | 24.04 | 22,645 |
| 2017-08-16 | Mcfarlane Neil F. (Chief Operating Officer) | Sale | 1,378 | 22.50 | 31,005 |
| 2017-06-14 | Aselage Steve (Chief Executive Officer) | Buy | 5,000 | 17.85 | 89,250 |
| 2016-11-22 | Aselage Steve (Chief Executive Officer) | Sale | 3,200 | 21.30 | 68,160 |
| 2016-11-21 | Aselage Steve (Chief Executive Officer) | Sale | 5,000 | 21.00 | 105,000 |
| 2016-09-01 | Shih Alvin (EVP of Research & Development) | Sale | 8,750 | 16.23 | 142,056 |
| 2016-06-01 | Shih Alvin (EVP of Research & Development) | Sale | 8,750 | 17.75 | 155,286 |
| 2016-03-04 | Meckler Jeffrey A (Director) | Buy | 5,000 | 15.31 | 76,565 |
| 2015-12-09 | Shih Alvin (EVP of Research & Development) | Sale | 8,750 | 20.83 | 182,262 |
| 2015-11-10 | Aselage Steve (Chief Executive Officer) | Sale | 30,000 | 18.72 | 561,600 |
| 2015-11-09 | Aselage Steve (Chief Executive Officer) | Sale | 30,000 | 18.77 | 563,100 |
| 2015-11-02 | Valeur Jensen Margaret E (General Counsel) | Sale | 50,000 | 20.75 | 1,037,500 |
| 2015-10-06 | Shih Alvin (EVP of Research & Development) | Sale | 8,750 | 20.55 | 179,786 |
| 2015-06-26 | Shih Alvin (EVP of Research & Development) | Sale | 27,916 | 32.70 | 912,853 |
Insider trading activities including stock purchases, stock sales, and option exercises
of TVTX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Travere Therapeutics, Inc. (symbol TVTX,
CIK number 1438533) see
the Securities and Exchange Commission (SEC) website.